Abstract #806649: Biochemical Testing for Cortisol Excess in Patients with Adrenal Incidentaloma

2020 ◽  
Vol 26 ◽  
pp. 26
Author(s):  
Grace Thomas
2011 ◽  
Vol 3 (3) ◽  
pp. 137-143
Author(s):  
Chris Armstrong ◽  
Janice L Pasieka ◽  
Adrian Harvey

ABSTRACT Unexpected incidental findings on cross-sectional imaging are becoming more commonplace in today's medical practice. These are likely due to ongoing improvements in the resolution of cross-sectional imaging and our increasing use of these tests combined with an aging population. In the case of the adrenal incidentalomas the majority of these represent benign nonfunctional adenomas and these are believed to have no malignant potential. On the contrary adrenocortical carcinoma (ACC) is an uncommon malignancy that carries a high mortality. Current biochemical and radiological follow-up investigations are expensive and are of limited benefit in the majority of cases of adrenal incidentalomas. This has created a dilemma for the proper diagnostic, clinical and radiologic follow-up as well as the triggers for surgical intervention. We present a series of three patients presenting with ACC that retrospectively arose from a small incidentally found adrenal lesion. Three patients were identified with ACC arising from an apparently benign adrenal incidentaloma. The average size of the original lesion was 1.6 cm whereas the average size of their adrenal tumor was 9.3 cm when they presented with ACC. Two of the three cases were found to develop functional tumors at the time of the diagnosis of ACC. Two of the three cases underwent surgical resection. The third patient was found to have metastatic disease at presentation and declined surgical intervention. We agree that current follow-up guidelines result in an increasing burden on our healthcare system; with expensive biochemical testing and imaging for what in most cases will prove to be a benign adenoma, these three cases have influenced our current strategies for follow-up. At the present time, we continue to follow the AAES/AACE guidelines. The development of improved methods of biochemical, radiologic and tissue diagnosis may help to improve our ability to recognize an ACC in this population at an earlier and potentially curable stage.


2018 ◽  
Vol 178 (5) ◽  
pp. 431-437 ◽  
Author(s):  
Edward Buitenwerf ◽  
Tijmen Korteweg ◽  
Anneke Visser ◽  
Charlotte M S C Haag ◽  
Richard A Feelders ◽  
...  

BackgroundA substantial proportion of all pheochromocytomas is currently detected during the evaluation of an adrenal incidentaloma. Recently, it has been suggested that biochemical testing to rule out pheochromocytoma is unnecessary in case of an adrenal incidentaloma with an unenhanced attenuation value ≤10 Hounsfield Units (HU) at computed tomography (CT).ObjectivesWe aimed to determine the sensitivity of the 10 HU threshold value to exclude a pheochromocytoma.MethodsRetrospective multicenter study with systematic reassessment of preoperative unenhanced CT scans performed in patients in whom a histopathologically proven pheochromocytoma had been diagnosed. Unenhanced attenuation values were determined independently by two experienced radiologists. Sensitivity of the 10 HU threshold was calculated, and interobserver consistency was assessed using the intraclass correlation coefficient (ICC).Results214 patients were identified harboring a total number of 222 pheochromocytomas. Maximum tumor diameter was 51 (39–74) mm. The mean attenuation value within the region of interest was 36 ± 10 HU. Only one pheochromocytoma demonstrated an attenuation value ≤10 HU, resulting in a sensitivity of 99.6% (95% CI: 97.5–99.9). ICC was 0.81 (95% CI: 0.75–0.86) with a standard error of measurement of 7.3 HU between observers.ConclusionThe likelihood of a pheochromocytoma with an unenhanced attenuation value ≤10 HU on CT is very low. The interobserver consistency in attenuation measurement is excellent. Our study supports the recommendation that in patients with an adrenal incidentaloma biochemical testing for ruling out pheochromocytoma is only indicated in adrenal tumors with an unenhanced attenuation value >10 HU.


2017 ◽  
Author(s):  
Nazli Gulsoy Kirnap ◽  
Ozlem Turhan Iyidir ◽  
Yusuf Bozkus ◽  
Lala Ramazanova ◽  
Asli Nar ◽  
...  

2017 ◽  
Author(s):  
Caoimhe Bonner ◽  
Usman Shah ◽  
Anna Hawkins ◽  
Anthony Pittathankal ◽  
Imran Syed ◽  
...  

2018 ◽  
Author(s):  
Kirsty Spence ◽  
Steven Hunter ◽  
Campbell Brown ◽  
Paul Thompson ◽  
Karen Mullan ◽  
...  

2019 ◽  
Author(s):  
Henry Dyer ◽  
MS Majeed ◽  
Fahad Wali Ahmed

2020 ◽  
Author(s):  
Wafa Benothman ◽  
Imen Halloul ◽  
Ghada Saad ◽  
Asma Benabdelkrim ◽  
Yosra Hasni ◽  
...  

2019 ◽  
Vol 4 (1) ◽  
pp. 64
Author(s):  
Nur Aisyah Zainordin ◽  
Fatimah Zaherah Mohamed Shah ◽  
Rohana Abdul Ghani

A 49-year old patient presented with symptoms of adrenal suppression following an attempt to withdraw Depo-Provera or Depot Medroxyprogesterone Acetate (DMPA) injection. She had been receiving DMPA injections for the past 16 years for contraception. She was initially prescribed DMPA by her gynaecologist but later on began obtaining the medication directly from a private pharmacy without prior consultation from her gynaecologist. Clinically, she had been experiencing significant weight gain and appeared cushingoid. Blood investigations confirmed partial adrenal suppression with presence of an adrenal incidentaloma. This case reports a known side effect of DMPA but occurring at a much lower dose than previously described. It also highlights the need to increase the awareness of the insidious side effect of DMPA and to avoid unsupervised use of the drug.


Sign in / Sign up

Export Citation Format

Share Document